Edwards Lifesciences Is Poised For Solid Growth In 2025—Analyst Highlights TAVR Growth, Margin Expansion
Edwards Lifesciences Corporation (NYSE:EW) shares are trading higher on Thursday. Stifel analyst Rick Wise upgraded Edwards from Hold to Buy, raising the price forecast to $90 from $75. Wise suggests ...
Edwards Lifesciences upped to Buy at Stifel on TAVR growth
Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.
Healio8h
CABG plus surgical AVR may suit certain older patients with aortic stenosis, CAD
CABG plus surgical aortic valve replacement for treatment of coronary disease and aortic stenosis was associated with better 5-year outcomes vs. PCI plus transcatheter aortic valve replacement in ...
Pharmabiz13h
Abbott introduces Navitor Vision in India, the next generation of heart valve technology designed to treat aortic stenosis
Our Bureau, Mumbai Thursday, January 30, 2025, 15:15 Hrs [IST] ...
Stifel raises Edwards Lifesciences stock to buy, target to $90
Stifel analysts upgraded Edwards Lifesciences (NYSE:EW) stock from Hold to Buy, citing potential growth acceleration in the Transcatheter Aortic Valve Replacement (TAVR) market. The firm also ...